[Thrombocyte aggregation inhibitors, anticoagulants and thrombolytic agents in heart diseases].
Darius
H
H
II. Medizinische Klinik und Poliklinik, Johannes-Gutenberg-Universität Mainz.
Erbel
R
R
Belz
G G
GG
Meyer
J
J
D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001780:Blood Coagulation Tests; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006331:Heart Diseases / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D013923:Thromboembolism / Q000097:blood / Q000188:drug therapy*
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors
Thrombozytenaggregationshemmer, Antikoagulanzien und Thrombolytika bei kardialen Erkrankungen.